Altimmune Inc (NAS:ALT)
$ 8.57 -0.16 (-1.83%) Market Cap: 609.54 Mil Enterprise Value: 471.93 Mil PE Ratio: 0 PB Ratio: 4.57 GF Score: 30/100

Altimmune Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript

Oct 12, 2021 / 07:30PM GMT
Release Date Price: $12.41 (+0.24%)
Patrick Trucchio
H.C. Wainwright & Co., LLC - Analyst

My name is Patrick Trucchio, and I am a Senior Biotech Analyst at H.C. Wainwright. It's my pleasure to introduce our next presenters, Vipin Garg, CEO; and Scott Harris, Chief Medical Officer of Altimmune, a clinical stage biopharmaceutical company focusing on developing treatments for obesity and liver disease. So I think maybe just to start, if we could talk about Altimmune's synthetic peptide technology platform, how did this come to be in its current form and what makes it differentiated from others in the market?

Vipin Garg
Altimmune, Inc. - President & CEO

Yes. Thanks, Patrick. Thank you for having us. So as you know, we are developing two different therapeutic candidates, both peptide-based, based on synthetic peptide platform technology, and we have made specific modifications to this peptide -- to these peptides to accomplish a specific goal. For instance, to increase half-life of the peptide molecule. So our first candidate is ALT-801, or Pemvidutide. It is a GLP-1 glucagon dual agonist

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot